Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results

Authors: Lauritsen, K.¹; Devière, J.²; Bigard, M.-A.³; Bayerdörffer, E.⁴; Mózsik, G.⁵; Murray, F.⁶; Kristjánsdóttir, S.⁷; Savarino, V.⁸; Vetvik, K.⁹; De Freitas, D.¹⁰; Orive, V.¹¹; Rodrigo, L.¹²; Fried, M.¹³; Morris, J.¹⁴; Schneider, H.¹⁵; Eklund, S.¹⁶; Larkö, A.¹⁶

Source: Alimentary Pharmacology & Therapeutics, Volume 17, Number 3, February 2003 , pp. 333-341(9)

Publisher: Blackwell Publishing

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Summary Aim

: To compare the efficacy of esomeprazole, 20 mg once daily, vs. lansoprazole, 15 mg once daily, for the maintenance treatment of patients with healed reflux oesophagitis. Methods

: During the initial open healing phase, 1391 patients with endoscopically verified reflux oesophagitis and a history of heartburn, with or without acid regurgitation, received esomeprazole 40 mg for 4-8 weeks. Patients who were healed (identified by endoscopy at 4 or 8 weeks) and symptom free were then randomized to receive 6 months of treatment with esomeprazole, 20 mg once daily, or lansoprazole, 15 mg once daily. Results

: Esomeprazole, 20 mg once daily, maintained a significantly higher proportion of patients in remission than lansoprazole, 15 mg once daily, over 6 months [83% (95% CI, 80-86%) of esomeprazole recipients compared with 74% (95% CI, 70-78%) of lansoprazole recipients; P < 0.0001; life table estimates]. When data were analysed according to baseline Los Angeles grade classification, esomeprazole, 20 mg once daily, achieved consistently higher remission rates across all grades of disease severity, whereas the efficacy of lansoprazole decreased to a greater extent with increasing severity of reflux oesophagitis. Conclusion

: Esomeprazole, 20 mg once daily, is more effective than lansoprazole, 15 mg once daily, in maintaining remission in patients with healed reflux oesophagitis.

Document Type: Research article

DOI: 10.1046/j.1365-2036.17.s1.7.x

Affiliations: 1: Odense University Hospital, Odense, Denmark; 2: University de Bruxelles Hôpital Erasme, Brussels, Belgium; 3: Hospitalier Universitaire de Nancy, Nancy, France; 4: Technical University of Dresden, Dresden, Germany; 5: Medical University Pécs, Pécs, Hungary; 6: Beaumont Hospital and Royal College of Ireland, Dublin, Ireland; 7: Læknastöðin Mjódd, Reykjavik, Iceland; 8: Università degli Studi di Genova, Genoa, Italy; 9: Mandal Sykehus, Mandal, Norway; 10: Coimbra University Hospital, Coimbra, Portugal; 11: Hospital de Basurto, Bilbao, Spain; 12: Hospital Central de Asturias, Oviedo, Spain; 13: Universitätsspital, Zurich, Switzerland; 14: Glasgow Royal Infirmary, Glasgow, UK; 15: Milpark Hospital, Johannesburg, South Africa; 16: AstraZeneca R&D, Mölndal, Sweden

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.